Search jobs 12-Jul-2021 Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772, a Novel 24 valent MAPS™ Vaccine for Streptococcus pneumoniae
Study results were selected for oral presentation at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
ASP3772 has also received FDA Breakthrough Therapy Designation
CAMBRIDGE, Mass. & TOKYO (BUSINESS WIRE) Affinivax, Inc. ( Affinivax ) and Astellas Pharma Inc. (“Astellas”) announced results from the Phase 2 clinical trial of ASP3772, a novel vaccine candidate targeting
Streptococcus pneumoniae. Developed using Affinivax’s proprietary MAPS™ (Multiple Antigen-Presenting System) platform technology, ASP3772 is designed to offer both B-cell (antibody) and T-cell immune protection against
VBI Vaccines Announces Presentation at the 2021 Annual Conference on Vaccinology Research financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
Black community members push to improve COVID-19 vaccine awareness
The 73-year-old woman said she hardly had any side effects.
Black community members push to improve COVID-19 vaccine awareness
Jewelean Jackson, the former board chair of the Community-University Health Care Center, documented her experience getting her second dose of the vaccine on Friday. My arm is still sore and it’s itching. Other than that, I’m fine. No temperatures, no fevers, no chills.
Jackson said she wanted to document the experience to shed light on the importance of the vaccine, while at the same time acknowledging the hesitancy that exists in the Black community.